EP3370841A1 - Device and method for isolation of potentially harmful material present in human or animal urine - Google Patents
Device and method for isolation of potentially harmful material present in human or animal urineInfo
- Publication number
- EP3370841A1 EP3370841A1 EP16794232.5A EP16794232A EP3370841A1 EP 3370841 A1 EP3370841 A1 EP 3370841A1 EP 16794232 A EP16794232 A EP 16794232A EP 3370841 A1 EP3370841 A1 EP 3370841A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- urine
- vaporization chamber
- protective structure
- vapor
- unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D1/00—Evaporating
- B01D1/30—Accessories for evaporators ; Constructional details thereof
- B01D1/305—Demister (vapour-liquid separation)
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/02—Treatment of water, waste water, or sewage by heating
- C02F1/04—Treatment of water, waste water, or sewage by heating by distillation or evaporation
- C02F1/048—Purification of waste water by evaporation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D3/00—Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
- B01D3/02—Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping in boilers or stills
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D3/00—Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
- B01D3/34—Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping with one or more auxiliary substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D5/00—Condensation of vapours; Recovering volatile solvents by condensation
- B01D5/0057—Condensation of vapours; Recovering volatile solvents by condensation in combination with other processes
- B01D5/006—Condensation of vapours; Recovering volatile solvents by condensation in combination with other processes with evaporation or distillation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2221/00—Applications of separation devices
- B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2257/00—Components to be removed
- B01D2257/91—Bacteria; Microorganisms
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2101/00—Nature of the contaminant
- C02F2101/30—Organic compounds
- C02F2101/305—Endocrine disruptive agents
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/003—Wastewater from hospitals, laboratories and the like, heavily contaminated by pathogenic microorganisms
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/005—Black water originating from toilets
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/20—Nature of the water, waste water, sewage or sludge to be treated from animal husbandry
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/34—Nature of the water, waste water, sewage or sludge to be treated from industrial activities not provided for in groups C02F2103/12 - C02F2103/32
- C02F2103/343—Nature of the water, waste water, sewage or sludge to be treated from industrial activities not provided for in groups C02F2103/12 - C02F2103/32 from the pharmaceutical industry, e.g. containing antibiotics
Definitions
- the disclosure relates to a device and a method for isolation of potentially harmful material, such as medical substances, present in dissolved state in human or animal urine.
- US3506543 discloses a device and a method of providing potable water from human urine under the conditions found in space travel.
- US20120055777 deals with reuse of the fluid fraction of the urine as a flushing liquid for restroom fixtures.
- none of these disclosures address the specific challenges that the removing of medical substances from urine presents.
- the disclosed devices are structurally unfit to ensure a quality-controlled, effective removal of medical substances from the urine in conjunction with an economic handling of the waste.
- WO2014/01 1 1 11 proposes to employ activated carbon in order to solve the problem of release of potentially harmful substances into the wastewater system.
- activated carbon is a lipophilic material with a poor ability to bind to hydrophilic medical substances dissolved in urine. Accordingly, large amounts of activated carbon are required if substantial amounts of urine are to be handled, which requires frequent changes of the active charcoal filter. A further problem is created hereby as these large amounts of activated carbon need to be disposed in a safe and environmentally friendly manner.
- urine samples containing antibiotics could be UV-treated in order to incapacitate antibiotics.
- further methods of radiation- and/or ozone treatment could be employed.
- the samples could also undergo a chemical treatment, such as hydrolysis or oxidation, having the same purpose.
- a chemical treatment such as hydrolysis or oxidation
- main objectives of the present invention are to enable a quality controlled, effective and economic isolation of dissolved substances in the urine.
- a general aspect of the invention is to isolate unwanted substances that are dissolved in urine by removal of substantial amounts of water from the urine.
- the water may be released to the public sewage system, whereas the remaining waste (unwanted potentially harmful substances plus urine solutes such as urea plus as little water as possible) may subsequently be incinerated in a high temperature oven or the like.
- the device has several important features which were found to be necessary in order to get a quality controlled, effective isolation of unwanted substances, and an economic handling of waste.
- the present disclosure relates to a device for processing of waste fluid containing potentially harmful material, in particular medical substances, present in dissolved state in human or animal urine.
- the device comprises a urine receiving unit for receiving urine and a vaporization chamber being in fluid communication with the urine receiving unit.
- the device further comprises a vapor evacuation unit for receiving vapor from the vaporization chamber and wherein the vapor evacuation unit comprises a protective structure arranged in fluid communication with the vaporization chamber.
- the protective structure features permeability to vapor while passage of mist-building droplets (aerosols) is prevented.
- a condensation unit suitable for receiving vapor from the vapor evacuation unit via the protective structure.
- the device also comprises means for heating the urine in the vaporization chamber, and possibly also a dosing unit for adding of a non-corrosive anti- foaming agent to said vaporization chamber.
- a replaceable waste container is arranged for receiving and isolating waste generated in the vaporization chamber through vaporization of urine.
- the waste container is in fluid communication with the vaporization chamber
- the device further comprises at least one heater adapted to heat the protective structure for preventing vapor from condensing at the protective structure.
- the device may further comprises a pump, which reduces pressure in the vaporization chamber such that a below atmospheric pressure is achieved. This gives a better control of the vaporization process in relation to the boiling point of the human or animal urine. This also reduces bad smell emanating out of the vaporization chamber.
- the device may further comprise means for heating the vaporization chamber at least such that the content of the vaporization chamber may boil at the below atmospheric pressure created by the means for reducing pressure.
- the boiling may be done at a first temperature being sufficient to vaporize said urine and to destroy all living microorganisms present in said urine,
- the boiling may be done at a first temperature being sufficient to vaporize said urine and the urine may be exposed to a second temperature sufficient to destroy all living microorganisms present in said urine.
- the device may further comprise a dosing unit for adding of a non-corrosive anti- foaming agent to the vaporization chamber in order to prevent foaming and/or corrosion during operation.
- the device may further comprise a urease dosing unit.
- the urease dosing unit may inject a dosage of urease at any step of the process.
- a dosage may be pre calculated or it may be adjusted based on measurements carried out in the process.
- the urease dosing unit may inject a dosage of urease at any step of the process.
- a dosage may be pre-calculated or it may be adjusted based on measurements carried out in the process.
- the urease dosing unit is arranged externally of the device suitable for isolation of material. This reduces the amount and generation of waste considerably prolonging both the operation time of the device and use of the waste container before the waste container must be replaced by a new empty one. This also improves the economy of the device.
- the device may further comprise an analytical unit arranged at any stage, either upstream or downstream of the protective structure.
- the analytical unit may be adapted to determine the amount of impurities in a condensate derived from the condensation unit and/or it may be adapted to determine the amount of impurities in the received urine or in the vaporization chamber.
- the analytical unit may determine the amount of impurities by measuring conductivity. In a further embodiment, the analytical unit may determine the amount of impurities by measuring absorbance. In yet a further embodiment, the analytical unit may determine the amount of impurities by measuring conductivity and absorbance.
- the device may comprise a microorganism reduction unit arranged so as to be in fluid communication with the urine receiving unit and with the vaporization chamber.
- the microorganism reduction unit may be arranged to heat up the received urine to a temperature exceeding 60 °C.
- the non-corrosive anti-foaming agent may comprise at least one of paraffins, fatty acids and tensids.
- the waste container should be releasably attached, sealable and exchangeable.
- the protective structure may comprise a maze structure, a plurality of porous deformable filling bodies or at least one polymer sponge.
- the protective structure operates as a demister.
- a first possible solution is having more than one protective structure comprising one or more demisters each according to the invention.
- Another possible solution according to the invention is having more than one protective structure, wherein at least one protective structure comprises one demister and at least one protective structure comprises more than one demister according to the invention.
- One possible solution according to the invention is having more than one protective structure, wherein at least one protective structure is coupled in series with at least one other protective structure in the fluid communication with the vaporization chamber according to the invention.
- Another possible solution according to the invention is having more than one protective structure, wherein at least one protective structure is coupled in parallel with at least one other protective structure in the fluid communication with the vaporization chamber according to the invention.
- the device may be dimensioned and assembled as a unit suitable for mobility within an indoor environment such as a hospital.
- the device according to the invention is also downscaled in weight, not only in size/dimensions, so that any transportation and lifting of it is facilitated. This is especially advantageous when moving it between floors by elevator and between rooms on the same floor and over doorsteps, which portability is of great importance at hospitals to make the use of the inventive device much more flexible.
- This downsized device according to the invention also reduces costs as the number of devices to buy may be held to minimum as one device is easily moved to another location indoor, e.g. between nursing wards in a hospital or in nursing homes or in eldercares or in welfare centers.
- This device has the same advantages if utilized in animal breeding facilities and/or in dairy farming when processing animal urine.
- the invention also relates to a method for processing of waste fluid containing potentially harmful material, in particular medical substances, present in dissolved state in human or animal urine.
- the method comprises the following steps:
- a vapor permeable protective structure which operates as a demister so as to prevent mist-building liquid droplets, including those carrying said potentially harmful material, from passing through said evacuation unit,
- the method may further comprise exposing the urine present in the vaporization chamber to a first below atmospheric pressure and simultaneously therewith exposing the urine to a temperatures sufficient to vaporize the urine by boiling and destroy all living microorganisms present in said urine, e.g. a first temperature sufficient to vaporize the urine by boiling and a second temperature sufficient to destroy ali living microorganisms present in said urine.
- the method may further comprise reducing the amount of urea in the urine held in the vaporization chamber by exposing said urine to urease.
- the step of reducing the amount of urea in the urine held in the vaporization chamber by exposing said urine to urease is performed by means of arranging an urease dosing unit externally of the device.
- the method may further comprise condensing the vapor downstream of the protective structure so that the amount of impurities in the evacuated vapor is determined using a condensate of the vapor that passed through the protective structure.
- the step of determining the amount of impurities in the evacuated vapor may comprise measuring conductivity or absorbance.
- the method may further comprise heating up the received urine to a temperature exceeding 60 °C prior to transferring it further.
- vaporization is here to be construed as a phase transition from the liquid phase to gas phase either through evaporation or through boiling.
- the beneficial effects of using below atmospheric pressure are the reduction of the smelling of urine during evaporation and a reduced fouling on the walls of the vaporization chamber due to the reduction of the boiling point of urine.
- a protective structure has proven to be a vital feature in effective removal of dissolved substances from the urine.
- the ability to isolate the antibiotic ciprofloxacine was 50 times more effective compared to when a protective structure was not utilized.
- a simple splash protection in the form of a metal plate in front of the vapor outlet was not sufficient.
- a protective structure with the ability to stop small water droplets in the form of aerosol was necessary to achieve an effective isolation of the dissolved substance.
- a suitable protective structure comprises at least one demister, i.e. a unit made of thin threads of metal arranged af fixed distances and working as a grid/net/lattice for effectively preventing aeroso!/droplets to pass through and enabling only for vapor to pass through the protective structure by enabling only
- demister i.e. a unit made of thin threads of metal arranged af fixed distances and working as a grid/net/lattice for effectively preventing aeroso!/droplets to pass through and enabling only for vapor to pass through the protective structure by enabling only
- the device and method according to the invention may utilize at least one protective structure to achieve an effective prevention of dissolved undesired substances, in particular medical ones, passing through the device.
- the device and method according to the invention may utilize at least two protective structures, either coupled in series and/or in parallel, to improve the prevention of dissolved undesired substances, in particular medical ones, passing through the device.
- the inventors have performed tests with and without any protective structure, e.g. any demister.
- the tests showed unexpectedly that at least one protective structure, e.g. at least one demister, in the device according to one aspect of the invention, is effective in preventing aerosols/droplets to pass through but reduces the
- a device for testing of this aspect of the invention vaporized 1 .3 litres of fluid/hour without a protective structure and only 0.5 litres of fluid/hour with a protective structure. The reason for this is that vapor and aerosol condense in the protective structure and flows back to the vaporization chamber of the device.
- the inventors have surprisingly discovered that the above condensing is eliminated or at least reduced by heating the protective structure, whereby the vaporization rate of the device then is about or at least 1 .1 liters of fluid/hour.
- the heating of at least one protective structure and/or at least one demister are/is achieved by arranging a heating element on the protective structure or the demister to heat it by being thermally connected therewith.
- the heating could also be achieved by arranging a heating element or heater externally of the protective structure and/or the demister to heat either the protective structure or the demister or both entities, e.g. electrically.
- the heating is possible to achieve by electrical means and/or heat exchanging.
- Urease unit to reduce waste production Urine contains 37.1 g solutes/liter and of that 13.4 g is urea (Puttman DF,
- a urease dosing unit may be present either upstream of the vaporization chamber, in the vaporization chamber or in the waste container. Urease converts urea to ammonium ions and carbon dioxide that is in gaseous state. In this way, the amount of solid-state waste material may be further reduced by up to about 30 %.
- waste is reduced in any device according to the invention, also in devices not having a protective structure according to the invention.
- any protective structure is very advantageous in the smaller sized device according to the invention.
- a protective structure combined with addition of urease reduces the amount of generated waste even further. This also aids in making a cleaner condensate. Less waste reduces the cost for incineration of waste and also for service/maintenance personnel due to need of fewer people handling this and due to a decreased cost for each waste container being recyclable and reusable.
- the inventors have performed tests to clarify that if addition of external urease is used, this usage is able to reduce the production of waste material from the machine/device to a great extent.
- 10 liters of urine were collected and fed to the evaporator. After all the water had been vaporized, this resulted in an amount of 3 dl waste. After cleaning of the device, another 10 liters of urine was added. However, before this urine was added to the device, this urine had been treated with 100KU Urease (100 000 units/gram solids) from Canavalia ensiformis for 30 minutes. Then, after evaporation of all the water in the urine, 2 di waste remained.
- treatment with external urease reduced the waste production by about 30 % compared to for example spontaneously generated urease producing bacteria that can simply not reduce the amount of waste to the extent and with the repeatability as achieved by the inventive device and method, especially not in humans.
- an analytical unit to evaluate the purity was used. This was done either through measuring conductivity of condensed vapor or by determining its absorbance.
- the calculated data may be registered, stored and/or presented to the device operator via the control panel.
- the device may have online monitoring of the quality of the isolation process. This continuous quality control ensures that the condensed vapor from the device is sufficiently pure to be released in the public sewage system.
- Urine may contain harmful microorganisms such as bacteria and viruses. This may result in a health hazard to humans that for instance are changing waste container. It is possible that the heating in the vaporization chamber is not sufficient to kill hardy microorganisms such as tuberculosis in spore form. In order to kill all microorganisms, a separate auxiliary heating unit may be employed. In this application, the terms auxiliary heating unit and microorganism sterilization unit are interchangeably used. Said unit heats the urine to at least 60° C for a sufficient time period in order to kill the microorganisms. It may also add antibacterial chemicals such as hydrogen peroxide for this purpose.
- Fig. 1 is a perspective view of a device for use in a care institution and according to an embodiment of the present invention.
- Fig. 2a is a schematic, cross-sectional view showing the protective structure being part of a device according to one embodiment of the present invention.
- Fig. 2b is a schematic, cross-sectional view showing the protective structure being part of a device according to another embodiment of the present invention.
- Fig. 3 is a schematical visualisation of a process performed by a device according to an embodiment of the present invention.
- Figs. 4A and 4B show flow charts of methods for isolation of material, in particular medical substances, present in dissolved state in human or animal urine according to the invention. .
- Fig. 1 is a perspective view of a device 1 for use in a care institution, such as an intensive care unit or a unit for treatment of infectious diseases, and according to an embodiment of the present invention. More specifically, different parts of the device 1 are shown. In this context, it is to be noted that pipes that in this embodiment would ensure fluid communication between different parts of the device have been left out from Fig. 1. Said parts are mounted on a base structure 2 comprising a first section 2a extending in a substantially horizontal plane and a second section 2b extending in a substantially vertical plane. The first section 2a has a first face that faces parts of the device, and a thereto opposite second face.
- the second section 2b has a first face that faces parts of the device and a thereto opposite, second face.
- Four peripherally positioned casters 4 are attached to the first section.
- the casters make the device 1 easily movable.
- a control cabinet 16 and a thereto associated control panel 7 are affixed to the second section 2b, more particularly to its second face.
- the urine receiving unit 3 may be embodied in different ways e.g. as a cylinder, a parallelepiped or a pipe.
- the unit may further comprise a hinged lid 1 that prevents inadvertent ejection of the urine e.g. due to sudden movements of the device.
- Urine is typically manually fed into the unit from a potty, a catheter bag or similar device. Urine from the receiving unit is transferred to the vaporization chamber 6.
- the vaporization chamber is typically made in stainless steel but may also be made from other material such as plastic or carbon fiber.
- its top surface 14 is provided with a plurality of pipe connections. Its bottom surface is also provided with a pipe connection.
- the chamber 6 is provided with at least one sensor for measuring process properties.
- the vaporization chamber 6 is also provided with stirring means (not shown) that in an exemplary embodiment are embodied as a centrally journalled arm rotating in a horizontal plane.
- stirring means (not shown) that in an exemplary embodiment are embodied as a centrally journalled arm rotating in a horizontal plane.
- the stirring is achieved by means of magnetic forces.
- the vaporization chamber 6 may be heated in different ways. In one embodiment, its walls are heated and the heat is subsequently conductively transferred to the urine in the chamber. In an alternative embodiment, a dedicated heating element may be at least partially immersed in the urine contained in the chamber. It is also envisaged to supply heat to the chamber via a medium such as water or steam.
- the vaporization chamber is, during operation, kept at below atmospheric pressure. This is achieved by use of a pump 15. The pump also assists the transferring of urine between different receptacles of the device by creating pressure differences. In one embodiment, the pump 15 is a liquid ring pump. The choice of this type of pump entails that the vapor from the vaporization chamber 6 may condense in the pump itself.
- a diaphragm pump or any other type of pump may be used.
- the pump is typically powered by a motor.
- a waste container 9 for receiving isolated material from the vaporization chamber 6 is releasably attached to the first section 2a of the base structure 2. It may be immobilized relative the base structure 2 by means of straps or similar locking means.
- the container is advantageously made in a suitable polymer material.
- a control cabinet 16, shown in Fig. 1 comprises a control unit.
- the control unit typically has a memory unit (not shown) and a processing unit (not shown) that is connected to the memory unit.
- the memory unit could be of the non-volatile kind, such as a flash memory or a RAM (Random Access Memory).
- a dedicated, executable computer program with computer instructions may be located in the memory unit.
- the processing unit is configured to carry out the instructions of the computer program.
- the computer program could be recorded on a carrier, typically a computer readable medium, prior to being loaded onto the memory unit.
- a control panel 17 is associated to the control cabinet 16.
- the control panel 17 is the interface between the operator of the device and the device 1 .
- Optional unit 12 is a buffer unit which renders the vaporization process at hand more stable by compensating for eventual disturbances in the feed of urine.
- Fig. 4B is a flow chart of the method for isolation of material, in particular medical substances, present in dissolved state in human or animal urine according to one embodiment of the invention.
- the method is used in a device 1 that has been described in connection with Figs. 1-3.
- the device 1 according to the invention may comprise an urease dosing unit for adding of urease to said vaporization chamber 6. This adding of urease may be done before any waste from the vaporization chamber is received by the waste container 9, the waste being generated in the vaporization chamber through vaporization of urine.
- the waste container 9 being in fluid communication with said vaporization chamber 6.
- the urease dosing unit may be arranged internally of the device 1 or externally of the device or at least one urease dosing unit may be arranged internally of the device and at least one urease dosing unit may be arranged externally of the device.
- the method flow chart in Fig. 4B comprises following steps: receiving S10 urine, transferring S20 the received urine into the vaporization chamber 6; exposing S40 the urine to temperatures sufficient to vaporize said urine and to destroy all living microorganisms present in said urine; evacuating S60 the vapor generated in the vaporization chamber; reducing S65 the amount of urea in the urine held in the vaporization chamber by exposing said urine to urease; and conveying S90 waste generated in the vaporization chamber through vaporization of urine to the waste container 9, once said waste meets a predetermined criteria or after a predetermined time period.
- the step S65 of reducing the amount of urea in the urine held in the vaporization chamber 6 by exposing said urine to urease is performed by means of arranging an urease dosing unit internally or externally of the device 1.
- the technical effect of adding urease to the urine, preferably, by addition of external urease, this usage of urease is able to reduce the production of waste from the device 1 to a great extent.
- the device 1 further comprises a protective structure 21 (shown in Figs. 2a and 2b) which hinders liquid (such as aerosol drops) but allows vapor to pass through.
- Figs 2a and 2b show cross-sectional views of two embodiments of the protective structure 21 according to the present invention.
- the structure 21 creates a physical obstacle that hinders liquid (such as aerosol drops), but allows vapor to pass through.
- the protective structure 21 is arranged in connection with a vapor evacuation unit 7 and is in fluid communication with the vaporization chamber 6.
- the protective structure 21 is vapor permeable.
- the protective structure 21 is vapor permeable and prevents passage of mist-building droplets (aerosols).
- the protective structure 21 is liquid-hindering but vapor-pervious.
- Non-limiting examples of the protective structure 21 may in some embodiments comprise a plurality of porous, deformable filling bodies shown in Fig. 2a. By way of example, such bodies may be made of steel wool or polymer sponge or a corresponding porous material that hinders liquid but is permeable to gas.
- the protective structure may comprise a metal net with a specified distance between the threads, such as a demister.
- these bodies could be embodied and arranged in many different ways.
- typical filling bodies may also include shapes such as saddles or rings, which may comprise packing, e.g. structured or knitted packing.
- Simple baffles are also envisaged.
- An alternative embodiment of the protective structure 21 is shown in Fig. 2b.
- the protective structure 21 may comprise a number of substantially two-dimensional, rigid objects for instance extending radially.
- the device 1 may be provided with more than one protective structure 21.
- the device 1 may be provided with at least one protective structure 21 comprising a demister or may be provided with at least one protective structure 21 being a demister in itself.
- the device 1 may be provided with at least one protective structure 21 comprising a demister and at least one protective structure 21 being a demister in itself.
- the device 1 may be provided with at least one protective structure 21 comprising more than one demister or may be provided with more than one protective structure 21 being a demister in itself.
- the technical effect to be achieved by introducing a protective structure 21 according to the present invention is the prevention of small, mist-building droplets (aerosol) that are created in the vaporization process, and possibly contain chemicals that are intended to be isolated in the vaporization chamber 6, from leaving the latter. Vapor that passed through the protective structure 21 may optionally condense in a condensation unit 24 for subsequent release into the waste water system.
- the technical effect to be achieved by introducing at least one protective structure 21 according to the present invention is the prevention of small, mist- building droplets (aerosol) that are created in the vaporization process and dragged along with the generated vapor, e.g. by adhering to droplets and/or by being part of the water forming the droplet at vaporization.
- the droplets/aerosol carried by the vapor comprise non-fluidic, i.e. solid, fractions in the form of chemicals comprising medical substances, such as antibiotics, cytostatics and nonsteroid, anti-inflammatory drugs intended to be isolated in the vaporization chamber 6, which substances then are prevented from leaving the latter and ending up in the drain and let out according to the invention.
- medical substances such as antibiotics, cytostatics and nonsteroid, anti-inflammatory drugs intended to be isolated in the vaporization chamber 6, which substances then are prevented from leaving the latter and ending up in the drain and let out according to the invention.
- test results presented in Example 1 below show a 50-fold increase in isolation efficiency of aerosol/droplet carried substances in the vaporization chamber 6 when at least one protective structure 21 was utilized, compared to when no protective structure 21 was used.
- Fig. 3 highly schematically shows one embodiment of the device with a urine receiving unit 3, vaporization chamber 6, means 15 for control of the pressure in the vaporization chamber, e.g. by achieving a below atmospheric pressure, means 31 for heating of the vaporization chamber 6, evacuating the vapor generated in the vaporization chamber through the vapor evacuation unit 7, prohibiting liquid, in particular aerosol/droplets comprising unwanted medical substances as defined above, to leave the vaporization chamber by the protective structure 21 , once the material still present in the vaporization chamber 6 meets a predetermined criteria or after a predetermined time period, evacuating this material from the vaporization chamber to the waste container 9.
- the device comprises a condensation unit 24, an analytical unit 27 to evaluate the cleanness of the vapor, a pump 15 to generate below atmospheric pressure and effluent to the sewer system.
- a condensation unit 24 to evaluate the cleanness of the vapor
- a pump 15 to generate below atmospheric pressure and effluent to the sewer system.
- valves V1 to V7 that, together with the pump, are used to create differences in internal pressure at least between the urine receiving unit, the vaporization chamber 6, the waste container 9 and the effluent to the sewage system such that the created pressure differences at least assist in transferring content at least between the urine receiving unit 3, the vaporization chamber, the waste container 9 and the sewage effluent.
- the analytical unit 27 is configured to determine the amount of impurities present in the condensed vapor either through measuring conductivity of the condensed vapor and/or by determining its absorbance.
- the analytical unit 27 is arranged either in connection with or downstream of the condensation unit 24.
- the device may feature a pressure gauge 25, a temperature sensor 26, a further means for measuring conductivity and/or absorbance, e.g. via the analytical unit 27, a first drain 28, cooling water 29, a sample 32, a second drain 33 and level sensors N1-N2.
- the valves V1 to V7 that are adapted to aid and enable control av fluid; waste and vapor flow in the device 1 are not explained in detail as use of such valves is common knowledge for the skilled person.
- the waste container 9 Once the waste container 9 is filled, it is removed and its content incinerated destroying all isolated harmful substances, in particular medical substances that otherwise would have been let out into the sewage together with the condensate.
- Fig. 4A is a flow chart of the method for isolation of material, in particular medical substances, present in dissolved state in human or animal urine according to one embodiment of the invention.
- the method is used in a device that has been described in connection with Figs. 1-3.
- the method comprises receiving urine S 0, transferring the received urine into a vaporization chamber 6 (S20), exposing the urine present in the vaporization chamber to a controlled pressure (e.g.
- the device 1 comprises at least one heater 40 for heating at least one protective structure 21 and/or at least one demister 21 to a temperature sufficient to prevent vapor from condensing at the protective structure.
- the method according to the invention comprises a step S100 of heating at least one protective structure 21 to a temperature sufficient to prevent vapor from condensing at each protective structure, e.g. by means of at least one heater 40 for each protective structure and/or demister 21.
- the heater 40 may heat the protective structure and/or demister 21 indirectly and/or directly to a temperature sufficient to prevent vapor from condensing on and/or in and/or at the protective structure and/or on and/or in and/or at the demister 21.
- At least one heater 40 is arranged externally of the device 1 suitable for isolation of material. In another embodiment, at least one heater 40 is arranged externally of at least one protective
- At least one heater 40 is integrated in at least one protective structure/demister 21 of the device 1. The same number of and operational and physical/technical coupling
- heater/-s 40 and/or protective structure/-s and/or demister/-s 21 are applicable for usage in the method according to the invention.
- the heating to prevent aerosol and/or droplets comprising substances, in particular medical ones, from passing through the protective structure 21 and increase the vaporization rate of the device 1 at the same time may be done by directly heating the protective structure.
- the heating to prevent the above aerosol/droplets from passing through the protective structure and increase the vaporization rate of the device at the same time may be done by indirectly heating the protective structure.
- the heating to prevent the above described aerosol/droplets from passing through the protective structure and increase the vaporization rate of the device 1 at the same time may be done by indirectly heating the demister 21 , if the protective structure comprises a demister, by increasing the temperature of the protective structure so that the protective structure by means of radiant heat and/or thermal conductivity and/or convection and/or induction heating.
- Another embodiment of the invention achieves the heating to prevent the above defined aerosol/droplets from passing through the protective structure and increase the vaporization rate of the device 1 at the same time by directly heating the demister 21 , if the protective structure comprises a demister or is in itself a demister, by increasing the temperature of the demister by means of thermal conductivity and/or induction heating.
- At least one or more protective structures 21 and/or at least one or more demisters 21 is utilized in the device 1 and method according to the invention to maintain or even improve the prevention of aerosols/droplets comprising substances, in particular medical ones, from passing through the protective structure/demister 21 and increase the vaporization rate of the device 1 at the same time.
- the received urine may also be collected in the auxiliary heating unit/ microorganism sterilization unit prior to transferring it to the vaporization chamber 6.
- This auxiliary heating unit is arranged to heat up the received urine to a temperature exceeding 60 °C for a time that is sufficient to kill microorganisms in step S40. In this way, bacteria and viruses that may be present in the urine can be destroyed.
- the generated vapor is led through the vapor-pervious, protective structure 21 in step S70, and condensed downstream of said protective structure in step S80.
- the condensed vapor has no or at least reduced or even a very low concentration of unwanted substances, in particular medical substances, such as the medical ones described in this disclosure.
- the amount of impurities, i.e. non-water molecules, in the condensed vapor may subsequently be determined. By way of example, this may be achieved through measuring conductivity of the condensed vapor or by determining its absorbance.
- a suitable way of continuously controlling the quality of the isolation process is obtained.
- the calculated data may be registered, and presented to the device operator via the control panel so as to enable online monitoring of the precision, i.e. the quality, of the isolation process.
- measurements may additionally be carried out upstream in the process, for example prior the vaporization chamber 6. Such measurements may be used to assist the control of dosing units such as urease dosing unit.
- the above mentioned measurements is preferably carried out by the analytical unit 27.
- a non-corrosive antifoaming agent is added in order to reduce foaming. Normally said agent is added to the boiling urine.
- the transfer of the urine between the urine receiving unit 3, the vaporization chamber 6 and the waste receiving container 9, and optionally at least the auxiliary heating unit 31 is gravity-assisted. Accordingly, in this embodiment all the receptacles are positioned along a vertical line such that an outlet of an upper receptacle, e.g. the vaporization chamber, is arranged in connection with an inlet of a lower receptacle, in the exemplary case the receiving container. The opening and closing of the valves arranged between the receptacles could then be actuated by the weight of the fluid content of each receptacle.
- Frozen MIS seq-opt E Coli are placed on an agar plate and incubated over night at 37 degrees C. The next day, one bacterial colony is placed in liquid growth medium. One day later 100 microliters are placed on several agar plates, respectively. On each of these plates, a mast disc impregnated with 20 microliters Ciprofloxacine solution was placed. LB agar plates ⁇ Sigma Aldrich) 35 g/liter, LB Broth 20 g/l.
- Sample 2 Antibacterial effect by condensed vapor from the device without a protective structure.
- Sample 3 Antibacterial effect by condensed vapor from the device with a protective structure.
- Liquid that passed through the device that lacked protective structure (Sample 2) had a bacterial inhibition zone of 26 mm, which approximately corresponds to 5 mg/l Ciproflaxine.
- Liquid that passed through the device that employed a protective structure had a bacterial inhibition zone of 1 1 mm, which approximately corresponds to 0.1 mg/l Ciproflaxine.
- the presence of a protective structure reduced the antibiotic concentration in the condensed vapor by about 50 times,
- the invention provides a great variety of possible designs and adaptation of a device for isolation of material present in urine.
- the invention may be utilized in existing industries, which do not already have such an inventive system.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hydrology & Water Resources (AREA)
- Engineering & Computer Science (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Organic Chemistry (AREA)
- Heat Treatment Of Water, Waste Water Or Sewage (AREA)
- External Artificial Organs (AREA)
- Processing Of Solid Wastes (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1551420A SE540041C2 (en) | 2015-11-03 | 2015-11-03 | Device and method for isolation of material present in human urine |
PCT/EP2016/075957 WO2017076745A1 (en) | 2015-11-03 | 2016-10-27 | Device and method for isolation of potentially harmful material present in human or animal urine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3370841A1 true EP3370841A1 (en) | 2018-09-12 |
Family
ID=57281192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16794232.5A Withdrawn EP3370841A1 (en) | 2015-11-03 | 2016-10-27 | Device and method for isolation of potentially harmful material present in human or animal urine |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3370841A1 (en) |
SE (1) | SE540041C2 (en) |
WO (1) | WO2017076745A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE539233C2 (en) | 2015-11-02 | 2017-05-23 | Pharmalundensis Ab | Method and apparatus to reduce waste production in an isolation process |
WO2018196990A1 (en) * | 2017-04-28 | 2018-11-01 | Pharmalundensis Ab | Method and apparatus for isolation of potentially harmful material |
JP6983695B2 (en) * | 2018-03-06 | 2021-12-17 | 日立造船株式会社 | Wastewater treatment method and wastewater treatment system |
CN112777678A (en) * | 2020-12-29 | 2021-05-11 | 杜守立 | Urine sample recovery processing device |
CN117142553B (en) * | 2023-10-30 | 2024-04-05 | 中科四维流体科技研究院(厦门)有限公司 | Laboratory waste liquid concentration treatment device |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3506543A (en) | 1964-07-13 | 1970-04-14 | Whirlpool Co | Urine recovery process by thermoelectric distillation and filtration |
FR2260549A1 (en) * | 1974-02-11 | 1975-09-05 | Saint Gobain Techn Nouvelles | Treatment of effluents from animal rearing units - to give fertilizer products and reusable water for cleansing units |
US4316774A (en) * | 1979-07-05 | 1982-02-23 | United Technologies Corporation | Thermoelectric integrated membrane evaporation system |
US5273719A (en) * | 1988-05-10 | 1993-12-28 | Japanic Corporation | Urine treating device |
AU653565B2 (en) * | 1990-12-21 | 1994-10-06 | Nikken Corporation | Raw sewage disposal apparatus and prefab for accomodating the same |
US8043509B2 (en) * | 2005-07-06 | 2011-10-25 | Sylvan Source, Inc. | Water purification system |
JP5369258B2 (en) * | 2008-01-18 | 2013-12-18 | 合同会社 矢部学術振興会 | Energy-saving freshwater production equipment |
US20120055777A1 (en) | 2010-09-03 | 2012-03-08 | Liquidbreaker Llc. | Distillation Urine Recycling Systems and Methods |
SE1250833A1 (en) | 2012-07-13 | 2014-01-14 | Ingela Skogvall Svensson | Absorbent unit |
-
2015
- 2015-11-03 SE SE1551420A patent/SE540041C2/en unknown
-
2016
- 2016-10-27 WO PCT/EP2016/075957 patent/WO2017076745A1/en active Application Filing
- 2016-10-27 EP EP16794232.5A patent/EP3370841A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
SE540041C2 (en) | 2018-03-06 |
SE1551420A1 (en) | 2017-05-04 |
WO2017076745A1 (en) | 2017-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3370841A1 (en) | Device and method for isolation of potentially harmful material present in human or animal urine | |
Pepper et al. | Pathogens in biosolids | |
Thakur et al. | Secondary transmission of SARS-CoV-2 through wastewater: concerns and tactics for treatment to effectively control the pandemic | |
BRPI0722008B1 (en) | method for treating a number of different waste streams by means of a local health facility purification system, and a purification system | |
CN216584621U (en) | Livestock sewage deodorizing device | |
CN111689645A (en) | Intensified sewage treatment method for infectious disease hospital | |
EP3615474B1 (en) | Method and apparatus for isolation of potentially harmful material | |
Homer et al. | Decontamination and digestion of infectious animal waste using a tissue dissolver in an animal biosafety level 3 facility | |
CN202099149U (en) | Small-sized medical sewage treater | |
CN108706666A (en) | A kind of precursor virus that eliminates off infects latent quick-reaction system | |
CN201485298U (en) | Sewage sterilizer | |
Ghernaout et al. | Searching If SARS-CoV-2 Subsists Following the Disinfection of Potable Water | |
Derbyshire et al. | The inactivation of viruses in cattle and pig slurry by aeration or treatment with calcium hydroxide | |
EP3615475B1 (en) | Method for treating wastewater comprising blackwater in a health care facility and health care facility | |
Molk et al. | Sanitization of an automatic reverse-osmosis watering system: removal of a clinically significant biofilm | |
Scanlon et al. | Inactivation of Mycobacterium bovis in cattle slurry by five volatile chemicals | |
Azar et al. | Investigation of optimal method for hospital wastewater treatment | |
CN205398294U (en) | Pure water preparation system | |
Sahlström | Recycled biowaste as a source of infection | |
EP2133313A2 (en) | Unit for decontamination of liquid and semi-solid waste | |
Zdeb et al. | Disinfection of rainwater as a way to their microbiological stability and safe use | |
Rathi | Hospital wastewater treatment scenario in India | |
CN208603957U (en) | A kind of sewage-treatment plant for medical sewage | |
Nobela | Sanitizing faecal sludge with lime in a context of emergency situations | |
CN107043180A (en) | A kind of pure water making system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180517 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190604 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20191112 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200603 |